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CHAPTER 1 – INTRODUCTION 
1.1 INNATE IMMUNITY AND ITS INTERPLAY WITH 
THE ADAPTIVE IMMUNE RESPONSES 
Evolutionary conserved defence mechanisms, collectively 
known as innate immunity, exert their impressive 
protective capacity in the majority of the living 
organisms, down to metazoans. On the contrary, adaptive 
immunity, an alternative system for pathogen 
recognition and elimination, can be found only in 
vertebrates as a consequence of their ability to generate 
antigen-specific lymphoid cells. Genetic and cellular 
processes (hypervariability, rearrangement of receptor 
gene segments and clonal selection) generate favorable 
somatic variants of antigen binding-receptors by which 
the adaptive immune cells specifically recognize 
pathogens and tissue insults [1,2,3]. Although the human 
immune responses are divided into these two branches, 
the immune network is the result of the extensive cross-
talk between the innate and adaptive responses. The 
innate immune system is considered as the first line of 
defense against infections; it augments the protection 
offered by anatomic and physiologic barriers and initiates 
the adaptive immune responses conferring a specific and 
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long lasting protection. The innate immune system 
consists of hematopoietic cells expressing the germline 
encoded pattern-recognition receptors (PRRs) such as 
macrophages, Dendritic Cells (DCs), granulocytes, mast 
cells and Natural Killer (NK) cells other than soluble 
factors such as cytokines and chemokines. By contrast, 
the adaptive immune system consists of T and B 
lymphocytes, expressing somatically generated antigen-
specific receptors, and antibodies (Fig.1) [4,5].  
 
 
Figure 1. Integrated human immune system. The human microbial 
defense system can be simplistically viewed as consisting of 3 levels: (1) 
anatomic and physiologic barriers; (2) innate immunity; and (3) adaptive 
immunity. In common with many classification systems, some elements are 
difficult to categorize. For example, NK T cells and dendritic cells could be 
classified as being on the cusp of innate and adaptive immunity rather than 
being firmly in one camp [5].  
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The innate immune cells are able to discriminate foreign 
molecules from self by PRRs that recognize conserved 
molecular patterns that are shared by many bacteria or 
viruses (pathogen-associated molecular patterns, 
PAMPs). The promptness of the innate responses 
depends on the availability of these receptors on immune 
cells before exposure to the antigens. The result of the 
PRRs/PAMPs interaction is the activation of 
proinflammatory signaling pathway leading to cytokine 
and chemokine release [6,7]. By this mechanism, 
macrophages recruit neutrophils to the site of infection 
where they ingest, kill and digest bacteria. Although still 
viewed as a short-lived effector cells which provide a first 
line of defence against pathogen by their phagocytic role, 
neutrophils perform several other important functions 
(Fig.2) [8]. 
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Figure 2. Neutrophils crosstalk with immune and non-immune cells 
in inflamed tissues and lymph nodes. Circulating neutrophils are 
stimulated by systemic pathogens to crosstalk with platelets and endothelial 
cells, and this triggers the coagulation cascade (not shown). In the presence 
of tissue damage, neutrophils leave the circulation and crosstalk with both 
resident and recruited immune cells, including mesenchymal stem cells 
(MSCs), macrophages, dendritic cells (DCs), natural killer (NK) cells and B 
and T cells. The figure shows the main outcome(s) of the effects that MSCs 
exert on neutrophils and of neutrophil crosstalk with other cell types. 
Neutrophils can also migrate to the lymph nodes either via the lymphatics 
(in a CC-chemokine receptor 7 (CCR7)-dependent manner, similarly to 
tissue DCs) or via the circulation (similarly to monocytes). In the lymph 
nodes, neutrophils can interact with DCs to modulate antigen presentation. 
TCR, T cell receptor; TLR, Toll like receptor [8]. 
 
 
The two main cellular types that exert supervisory 
functions in the immune responses are the macrophages 
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and dendritic cells. These mononuclear phagocytes, both 
derived from blood monocytes, are able to recruit the 
immune cells to the site of infection by chemotactic 
cytokines and modulate their function by several soluble 
or membrane-bound molecules. Moreover, they are 
known as “professional” antigen presenting cells (APCs) 
because of their capability to present antigenic molecules 
to T lymphocytes, so initiating the adaptive immune 
responses. Among APCs, only dendritic cells have the 
ability to induce a primary immune response in naïve T 
lymphocytes; therefore, they play a pivotal role in the 
induction of the adaptive immunity (Fig.3) [9].   
 
 
Figure 3. Functional profile of immature and mature DCs. Immature 
DCs efficiently sample antigens from the surrounding environment by 
macropinocytosis, receptor-mediated endocytosis and phagocytosis. On the 
other hand, they express a high diversity of receptors which enable them to 
recognize PAMPs, cytokines, chemokines and other stress signals. Upon 
maturation, they become capable to activate naïve T cells (signals 1 and 2) 
promoting the differentiation of newly activated T lymphocytes into effector 
cells (signal 3) [9]. 
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Cytolytic effector functions against infected cells or 
tumor cells in the innate immunity are performed by the 
natural killer cells which do not bear a specific antigen 
receptor. Moreover, they release several 
immunoregulatory cytokines that impact on DCs, 
macrophages and neutrophils as well as on the adaptive 
immune response. Conversely, T and B lymphocytes act 
to enhance elements of the innate system by cytokine or 
antibody production, respectively [10]. Therefore, the 
tissue homeostatic maintenance and the resolution of 
infection are dependent on this strong interplay between 
the two arms of the immune system while a 
dysregulation of this crosstalk could lead to pathology 
(Fig.4). 
 
12 
 
 
Figure 4. The interface between innate and adaptive immunity and 
the consequences of success or failure. Essential to the successful 
removal of pathogens is the early recognition of microbes by components of 
the innate immune system. These involve the complement system, 
specialized receptors expressed on NK cells and the family of TIRs that are 
expressed on myeloid as well as lymphoid cells and that recognize specific 
microbially derived molecular structures. Successful engagement of some of 
these pathways lead to pathogen eradication and host immunity (green). 
Failure to efficiently discriminate self from non-self in innate as well as 
adaptive immunity can lead to pathogen proliferation and ultimately sepsis 
(red) and may also be the cause for development and maintenance of 
autoimmune disease and allergy (red). CD40L, CD40 ligand; IFN, 
interferon; MHC, major histocompatibility complex; PMN, 
polymorphonuclear cells; TCR, T cell receptor; NCR, natural cytotoxicity 
receptor; NCR-L, natural cytotoxicity receptor-ligand [11]. 
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1.2 Ontogeny and heterogeneity of 
mononuclear phagocytes 
The mononuclear phagocyte system could be roughly 
described as a subgroup of leukocytes of myeloid lineage 
that circulate in the blood as monocytes to further 
differentiate into a range of tissue macrophages and 
dendritic cells (DCs). These phagocytic cells mediate 
essential functions in the steady state and during 
inflammation including phagocytosis, cytokine 
production, initiation of adaptive immunity, tissue 
genesis and homeostasis.  
Recent evidence, on the basis of transplantation studies 
in mice, strongly indicates that monocytes are not simply 
transitional cells but they are highly heterogeneous, 
adopting different activation states and changing their 
function in response to microenvironmental signals.  
Blood monocytes originate, in vivo, from hematopoietic 
stem cell-derived progenitor (HSC) and downstream, the 
commitment steps in the bone marrow follow along the 
common myeloid progenitors (CMP) and the granulocyte-
macrophage precursors (GMP). Within the bone marrow, 
the GMPs differentiate to CX3CR1+ ckit+ CD115+ 
macrophage and dendritic cell progenitors (MDP) that 
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give rise to monocytes, several macrophage subsets and 
DCs (Fig.5) [12,13].  
 
 
Figure 5. Differentiation of the macrophage/DC progenitor and 
origin of macrophage and DC subsets [13]. 
 
Two different groups have recently described the common 
DC precursor (CDP), originating from mouse MDP in the 
bone marrow, that specifically generate classical DCs 
(cDCs) and plasmacytoid DCs (pDCs) but not monocytes 
[14,15]. cDCs are professional APCs specialized to 
capture antigens in most tissues and further regulate T 
cell responses in lymphoid organs [16]. By contrast, the 
primary function of pDCs is the rapid and massive 
secretion of type I interferons (IFN-α/β) to respond to 
viral infection [17]. 
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The MDPs give rise to two distinct subsets of mouse 
monocytes on the basis of chemokine receptor expression 
and the presence of specific surface molecules. The first 
subset, termed “inflammatory”, express Ly6c (Gr1+), 
CCR2 and L-Selectin and are selectively recruited to sites 
of inflammation and infection. This subset generates 
macrophages and the so-named Tip-DCs characterized by 
the production of inflammatory mediators such as tumor 
necrosis factor (TNF)-α and nitric oxide (NO). This group 
of DCs represents short-lived cells whose main function 
is to kill bacteria rather than to regulate T-cell function 
[18]. The second subset of monocytes express high levels 
of the chemokine receptor CX3CR1 and the integrin LFA-
1 but not Ly6c (GR1-), CCR2 and L-Selectin. They are 
termed “resident” because of the patrolling behavior in 
the vasculature in the steady state. This subset of 
monocytes rapidly extravasates after infection and 
contributes to early inflammatory response. However, 8h 
after infection, they stop to produce the inflammatory 
mediators while the Gr1+ monocytes are now the main 
producers. It seems that after infection the GR1- 
monocyte subset initiates an M2 macrophage 
differentiation program that are proposed to be involved 
in tissue repair (Fig.6) [19,20].  
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Figure 6. Differentiation of DCs and macrophages in mice. In the 
bone marrow, hematopoietic stem cells (HSCs) produce myeloid (MP) and 
lymphoid (LP) committed precursors. MPs give rise to monocyte, 
macrophage, DC precursors (MDPs). MDPs give rise to monocytes, some 
population of macrophages, and common DC precursors (CDPs). Two 
monocyte subsets, Ly6C+ and Ly6C-, leave the bone marrow to enter the 
blood. CDPs give rise to preclassical dendritic cells (pre-cDCs) and 
plasmacytoid dendritic cells (PDCs). Pre-cDCs circulate in blood and enter 
lymphoid tissue, where they give rise to CD8α+ and CD8α- cDCs, and 
nonlymphoid tissues, where they may give rise to CD103+ lamina propria 
DCs (lpDCs). Under homeostatic conditions, Ly-6C- monocytes may 
contribute to alveolar macrophages (MФ), and Ly-6C+ monocytes can become 
CX3CR1+ lpDCs in nonlymphoid tissues. During inflammation, Ly-6C+ 
monocytes give rise to monocyte-derived DCs, for example, tumor necrosis 
factor (TNF) and inducible nitric oxide synthase (iNOS)-producing dendritic 
cells (Tip-DCs), inflammatory macrophages, and may contribute to myeloid-
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derived suppressor cells (MDSCs) associated with tumors. They are also 
suspected (dashed arrow) to contribute to microglia and Langherans cells in 
selected experimental conditions. Microglia and Langherans cells can renew 
independently from the bone marrow (curved arrow). HSCs can also leave 
their bone marrow niche (dashed arrow) and enter peripheral tissues, where 
they differentiate to myeloid cells during inflammation. It is unclear at this 
time whether LPs contribute substantially to PDCs and cDCs (dashed 
arrow) [20]. 
 
 
Although the mouse monocytes exhibit remarkable 
plasticity, as highlighted by in vivo studies in mouse 
models, the human myeloid cell differentiation and 
function are not fully understood as yet.  However, as 
described in mice, human monocytes can be divided into 
two major subsets on the basis of surface CD14 and CD16 
expression (CD14+CD16- and CD14+CD16+). The human 
CD14+CD16- classical monocytes, which comprise 
approximately 95% of human blood monocytes, express 
the chemokine receptor CCR2 and produce TNF, IL-1 
and IL-6 in response to LPS stimulation in vitro 
suggesting that they are the counterparts of mouse Gr1+ 
inflammatory monocytes. By contrast, human 
proinflammatory CD16+ monocytes, equivalent to GR1- 
mouse monocytes, express high levels of CX3CR1 and are 
the main producers of TNF-α [21,22,23]. The CD16+ 
monocytes can be further divided according to their high 
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or low levels of CD14 expression into two smaller 
subpopulations, the intermediate CD14++CD16+ and the 
non-classical CD14+CD16++ monocytes [24]. The former 
have phagocytic activity and produce proinflammatory 
cytokines in response to different stimuli whereas the 
latter are weak phagocytes and respond to viral stimuli 
through TLR7 and TLR8 [25]. Therefore, the 
differentiation and contribution to immune defence of 
human and mice monocyte subsets appear to be similar 
even though they are not fully equivalent (Table 1 [26]). 
 
 
 
1.3 Macrophage function and polarization 
Blood monocytes are recruited into the tissue where they 
differentiate into macrophages in steady state and during 
inflammation. Macrophages can acquire functional 
specialization and phenotypes based on their anatomical 
location including Kupffer cells in the liver, osteoclasts in 
the skeletal system, microglial cells of the brain, alveolar 
19 
 
macrophages of the lung and histiocytes of the connective 
tissue (Fig.7) [27]. 
 
 
Figure 7. Tissue macrophages perform important homeostatic 
functions. Mononuclear phagocytes are generated from committed 
hematopoietic stem cells located in the bone marrow. Macrophage precursors 
are released into the circulation as monocytes and quickly migrate into 
nearly all tissues of the body, where they differentiate into mature 
macrophages. Various populations of mature tissue macrophages are 
strategically located throughout the body and perform important immune 
surveillance activities, including phagocytosis, antigen presentation and 
immune suppression [27]. 
 
 
Macrophages are “professional” phagocytic and antigen 
presenting cells but they are also involved in tissue 
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remodeling and repair under homeostatic and damage 
conditions [28]. Therefore, the macrophage lineage 
includes versatile and plastic cells with distinct functions 
that are specified by the exposure to microenvironmental 
signals. Mirroring the T-cell literature, two well-
established polarized phenotypes have been described: 
classically activated macrophages (M1 macrophages) and 
alternatively activated macrophages (M2 macrophages) 
(Fig.8). 
 
 
Figure 8. Schematic representation of the M1- and M2-polarized 
macrophages. The polarizing signals and salient molecular, metabolic and 
functional characteristic of these macrophages are indicated (adapted from 
[28]). 
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M1 macrophages arise in response to interferon-γ (IFN-γ) 
alone, typically produced by NK and T helper 1 cells, or 
in combination with microbial stimuli (eg LPS) or 
cytokines (eg TNF and GM-CSF). M1 cells have 
microbicidal activity, antigen presenting function and 
express pro-inflammatory cytokines (IL-1, TNF, IL-6). In 
contrast, M2 macrophages arise in response to 
interleukin-4 (IL-4) or IL-13, which are produced by T 
helper 2 cells. M2 cells express the mannose receptor 
CD206, arginase 1 and IL-10 among others. They are 
associated with anti-inflammatory and homeostatic 
functions linked to fibrosis and tissue repair [29]. 
Moreover, the macrophages that infiltrate tumor tissue, 
named tumor-associated macrophages (TAMs), share 
several properties with polarized M2 cells. They promote 
immunosuppression, angiogenesis, cell motility and 
tumor progression [30].  
Accumulating evidence exists that several transcription 
factor and epigenetic regulation contribute to 
macrophage differentiation and polarization. The 
transcription factor PU.1 binds to genomic enhancers and 
controls the regulatory regions in which transcription 
factors operate to modulate macrophage identity. M1 
stimuli like LPS, GM-CSF and IFN-γ activate the 
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transcription factors STAT1/2, IRF5 and NF-κB that 
regulate the expression of inflammatory genes 
characteristics of the M1 polarization state. By contrast, 
M2 stimuli like IL-4 and IL-13 active STAT6, PPARγ and 
IRF4 that mediate the M2 polarization of macrophages 
(Fig.9) [31]. 
 
 
 
Figure 9. Signal transduction pathways to M1 and M2 macrophage 
polarization. Signaling pathways implicated in M1 and M2 macrophage 
polarization are indicated. An initial stimulus leads to the activation of 
sequence-specific transcription factor that eventually mediate the changes in 
the transcriptional output. The main genes that are characteristic of either 
the M1 or the M2 polarized state are also shown. Arg, arginase 1; C/EBPβ, 
cAMP-responsive element-binding protein; CSF, colony-stimulating factor; 
IFNγ, interferon-γ; IL, interleukin; IRF, interferon-regulatory factor; JAK, 
janus kinase; LPS, lipopolysaccharide; Mrc1, macrophage mannose receptor 
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1; MSK, mitogen- and stress-activated kinase; NK-κB, nuclear factor-κB; 
Nos2, nitric oxide synthase 2; PI3K, phosphoinositide 3-kinase; PPARγ, 
peroxisome proliferator-activated receptor-γ; Retnla, resistin-like-α; STAT, 
signal transducer and activator of transcription; TLR4, Toll-like receptor 4 
[31].  
 
 
1.4 Natural Killer cells and their receptor 
repertoire 
Natural Killer (NK) cells are a subset of lymphoid cells 
that play a pivotal role in the innate immune responses. 
Differently from antigen-specific T and B lymphocytes, 
NK cells recognize and kill target cells, such as 
transformed or virus-infected cells, without prior 
sensitization [32].  
The level of CD56 (Neuronal cell adhesion molecule) and 
CD16 (Fcγ receptor III) expression defines the two major 
NK cell subsets both arising from the bone marrow 
CD34+ hematopoietic progenitor cells (HPCs) (Fig.10).  
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Figure 10. Model of human NK-cell development. (1) Bone marrow–
derived CD34+CD45RA+ HPCs circulate in the blood and (2) extravasate 
across lymph node high endothelial venules to enter the parafollicular space. 
There, (3) pro-NK cells are activated to progress through distinct stages of 
maturation (far right) to create both CD56bright and CD56dim NK cells. 
Maturing CD56dim NK cells return to the circulation via the efferent lymph 
(4), whereas some CD56bright NK cells remain within the secondary 
lymphoid tissue to interact with DCs (5) [33]. 
 
 
The CD56bright subset, which expresses low or no levels of 
CD16, produces high amounts of immunoregulatory 
cytokines including IFN-γ, TNF-β, IL-10, IL-13 and GM-
CSF. By contrast, the CD56dimCD16bright subset, which 
constitutes approximately 90% of human NK cells, is 
mainly responsible for natural cytotoxicity against NK-
sensitive targets (Fig.11) [34,35]. 
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Figure 11. Scheme of human natural killer (NK)-cell subsets. (a) 
CD56bright NK cells produce high levels of cytokines following stimulation 
with monokines. This subset has low-density expression of CD16 and 
exhibits low natural cytotoxicity and antibody-dependent cellular 
cytotoxicity (ADCC), but potent lymphokine activated killer (LAK) activity. 
CD56bright NK cells have high-level expression of the inhibitory CD94–
NKG2A C-type lectin NK receptor (NKR) but have low level expression of 
killer Ig-like receptors (KIRs). This NK-cell subset expresses a number of 
cytokine and chemokine receptors constitutively, including the high-affinity 
interleukin-2 receptor (IL-2Rαβγ), c-kit and CC-chemokine receptor 7 
(CCR7). The adhesion molecule L-selectin, which, in combination with 
CCR7, is involved in trafficking to secondary lymph nodes, is also found on 
CD56bright NK cells. (b) By contrast, CD56dim NK cells produce low levels of 
NK-derived cytokines but are potent mediators of ADCC, LAK activity and 
natural cytotoxicity, and have a more granular morphology than CD56bright 
NK cells. The CD56dim NK-cell subset has high-level expression of KIRs. 
These cells have distinct expression of cytokine (e.g. IL-2Rβγ) and chemokine 
(e.g. CXCR1 and CX3CR1) receptors. CD56dim NK cells lack L-selectin but 
highly express PEN5–P-selectin glycoprotein ligand-1 (PSGL-1), another 
adhesion molecule [Adapted from 34].  
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NK cells express several germ-line encoded inhibitory 
and activating receptors, and their activation state 
results from a fine balance between the inhibitory and 
activating signals (Fig.12) [36]. 
 
 
Figure 12. The dynamic regulation of NK cell effector function. NK 
cells sense the density of various cell surface molecules expressed at the 
surface of interacting cells. The integration of these distinct signals dictates 
the quality and the intensity of the NK cell response. NK cells spare healthy 
cells that express self-MHC class I molecules and low amounts of stress-
induced self molecules (A), whereas they selectively kill target cells “in 
distress” that down-regulate MHC class I molecules (B) or up-regulate stress 
induced self molecules (C). +, activating receptors;  –, inhibitory receptors 
[36]. 
 
 
At the moment, three main families of Human Leukocyte 
Antigen (HLA) class I receptors have been described: the 
human Killer cell Ig-like receptors (KIR) and the human 
Ig-like transcript (ILT), which belong to the 
immunoglobulin (Ig) superfamily and bind a large 
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number of HLA class I alleles; and the C-type lectin-like 
receptors (NKG2/CD94) which recognize the HLA-E 
molecules [37]. The inhibitory receptors belonging to 
these families, such as KIR2DL or KIR3DL (with a “long” 
cytoplasmic domain), the heterodimer NKG2A/CD94 and 
the ILT receptors, share one or more Immunoreceptor 
Tyrosine based Inhibitory motifs (ITIM) in their 
cytoplasmic tail that suppress the NK cell responses. By 
constrast, KIR2DS or KIR3DS (with a “short” 
cytoplasmic domain) and the heterodimer NKG2C/CD94, 
lack ITIM but interact with the DAP12 protein that 
contains the Immunoreceptor Tyrosin based Activation 
motifs (ITAM) [38]. 
The principal NK cell activating receptors include the 
Natural Cytotoxicity Receptors (NCR), DNAM-1 and 
NKG2D. The NCR family includes NKp30, NKp44 and 
NKp46 that belong to the Ig superfamily and form a 
complex with an ITAM-bearing accessory protein. The 
molecular ligands of NCRs still remain elusive despite 
their involvement in the lysis of diverse tumor target 
cells [39]. The other two important activating NK 
receptors that cooperate in the induction of tumor or 
virus-infected cell killing are the DNAX accessory 
molecule-1 (DNAM-1) and NKG2D (Natural Killer group 
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2, member D). The poliovirus receptor (PVR) and Nectin-
2 have been identified as the DNAM-1 ligands [40] 
whereas NKG2D interacts with several molecules. These 
include the highly polymorphic Major Histocompatibility 
Complex (MHC)-I related chains A and B (MIC-A and 
MIC-B) and the UL-16 binding protein (ULBP-
1,2,3,4,5,6) that are normally expressed on infected or 
transformed cells (Fig.13) [41]. 
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Figure 13. Major inhibitory and activating NK cell receptors and 
their ligands involved in AML. NK cell activation upon contact with a 
target cell depends on the balance between inhibitory and activating signals 
relayed through a variety of NK cell receptors after binding with specific 
ligands on the target cell. Most NK cell receptors bind their ligands through 
extracellular immunoglobulin-like (Ig) domains, while NKG2 hetero- or 
homodimers have C-type lectin-binding domains. Inhibitory receptors, such 
as the leukocyte immunoglobulin-like receptor-1 (LIR-1), inhibitory KIRs 
and heterodimers of CD94 and NKG2 isoforms A and B, have cytoplasmic 
tails containing multiple immune-receptor tyrosine-based inhibitory motifs 
(ITIMs). After ligation of the receptors these ITIMs become phosphorylated, 
allowing them to decrease activating cell signaling through the recruitment 
of phosphatase enzymes. Activating receptors include the activating forms of 
KIRs and CD94/NKG2 heterodimers, NCRs, DNAM-1, NKG2D homodimers, 
CD16 and 2B4. Many of these receptors have intracellular domains 
containing immunoreceptor tyrosine-based activation motifs (ITAMs), such 
as the transmembrane DAP12 adapter protein. As opposed to ITIMs, ITAMs 
facilitate activating cell signaling when phosphorylated following receptor 
ligation. Instead of via ITAMs, the NKG2D and 2B4 receptors promote 
activation through phosphorylation of the tyrosine residues of the tyrosine-x-
x-methionine (YxxM) motif in the DAP10 adapter protein and in the 
immunoreceptor tyrosine-based switch motifs (ITSMs), respectively. For 
DNAM-1, signaling involves phosphorylation of Ser329 by protein kinase C 
[Adapted from 42].  
 
 
Accumulating evidence indicates that elevated levels of 
soluble MIC-A/B [43,44,45] and ULBPs [46,47] can be 
found in the culture supernatants of several tumor cells 
as well as in the sera of patients affected by different 
cancers. The release of these NKG2D ligands, by 
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proteolytic shedding or through exosomes, promotes 
escape of tumors from NKG2D-mediated 
immunosurveillance that results from a reduction in cell 
surface density of the membrane-bound NKG2D ligands 
or a down-regulation of NKG2D receptor on the immune 
effector cells. 
 
 
1.5 HLA class I antigen processing and 
presenting machinery 
The HLA-ABC antigens, also called Major 
Histocompatibility Complex (MHC) class I, are highly 
polymorphic glycoproteins expressed on the cell surface 
of almost all nucleated cells. These classical HLA class I 
molecules consist of a heavy chain of about 44-45 kDa, 
encoded by the HLA class I genes located on the short 
arm of chromosome 6, and a soluble light chain (β2-
microglobulin) of 12 kDa encoded by a gene located on 
chromosome 15. The ectodomain of the alpha heavy chain 
can be divided into three globular domains (α1, α2, α3). 
The region between the α1 and α2 domains form the 
antigen binding domain that accommodates antigenic 
peptides ranging from 8 to 11 amino acids in length 
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whereas the α3 domain binds the CD8 glycoprotein which 
is important for the recognition of antigen by cytotoxic T 
cells (Fig.14) [48,49]. 
 
 
Figure 14. Overview of the structure of the HLA class I.  The heavy 
chain is shown in cyan, β2m in purple, and the peptide in yellow [Adapted 
from 50]. 
 
 
The principal role of the classical HLA class I molecules 
is to bind and present intracellular antigenic peptides to 
T-cell receptors (TCRs) leading to killing of the infected 
or transformed target cells. Therefore, the high degree of 
HLA polymorphism increases the range of adaptive 
immune responses that different individuals can mount 
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against a broad spectrum of antigenic peptides. 
Moreover, several HLA class I alleles are associated with 
different autoimmune or inflammatory diseases probably 
because the peptide binding cleft, which is the more 
polymorphic region, could impair the peptide binding as 
well as the TCR recognition [51]. 
Loading of high affinity intracellular pathogen or self-
derived peptides onto HLA class I molecules is 
accomplished within the endoplasmic reticulum (ER) 
through the so called antigen processing machinery. This 
is a quality control machinery that allows the expression 
of correctly assembled trimeric HLA-I/β2m/peptide 
complex on the cell surface where it displays the 
antigenic peptides to CD8+ CTL which, in turn, trigger a 
specific adaptive immune response. Not surprisingly, 
many transformed or virus-infected cells display several 
abnormalities in this pathway that allows their escape 
from immune surveillance [52,53,54]. 
The majority of antigenic epitopes contained within 
various intracellular proteins are generated via the 
constitutive multicatalytic 26S/20S proteasome complex. 
The peptide repertoire is however enlarged by the 
alternative IFN-γ-induced immunoproteasome which 
exhibits an altered catalytic activity on peptide 
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substrates. The cytosolic peptides generated by 
proteasome are, then, actively translocated to the ER 
lumen by the transporters associated with antigen 
processing (TAP1/TAP2) where they are further trimmed 
by ER aminopeptidases (ERAP-1/2). These peptidases 
ensure that the antigenic epitopes reach the optimal 
length required to fit the peptide-binding pocket of HLA 
class I molecules. The newly synthesized HLA class I 
heavy chains rapidly associate with the ER chaperone 
Calnexin and the thiol oxidoreductase ERp57 that 
facilitate their folding and interaction with the β2m. 
Therefore, only the correctly folded HLA-I/β2m 
heterodimers are released from calnexin and recruited 
into the Peptide-Loading Complex (PLC) which ensures 
that only high-affinity peptides are loaded onto HLA-
class I molecules and presented to T-lymphocytes. The 
PLC is a quality control machinery organized around the 
TAP molecules by the adapter protein Tapasin (Tsn), 
which recruits the peptide-receptive HLA class I 
molecules, now associated with the chaperone 
Calreticulin (CRT). The complex is further stabilized by 
the disulfide isomerase ERp57 which forms a stable 
conjugate with Tsn and CRT (Fig.15). 
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Figure 15. ER quality control and MHC class I assembly. MHC class I 
assembly in the ER. The folding of the MHC class I HC and formation of 
disulfide bonds in the α2 and α3 domains is assisted by CNX and ERp57. The 
HC then assembles with β2m to generate an empty heterodimer that is 
highly unstable for most MHC class I alleles. The HC/β2m dimer is 
stabilized by association with tapasin, ERp57, CRT, and TAP in the PLC, 
where it awaits peptide binding. TAP transports peptides generated from 
cytosolic proteins by the proteasome into the ER lumen where they are 
further trimmed by ERAAP/ERAP1 (mice and humans) and ERAP2 
(humans only). Once high affinity peptides of the appropriate length are 
generated, they are loaded onto empty MHC class I molecule by the PLC. 
Peptide binding induces dissociation of MHC class I from the PLC and it 
subsequently traffics to the cell surface [Adapted from 55]. 
 
 
After the binding of a peptide, ER resident chaperones 
are released and the HLA class I molecules traffic via the 
secretory pathway to the plasma membrane (Fig.16). 
Here, the peptides derived from pathogen or mutated 
proteins are recognized by the specific TCR on CD8+ T 
cells triggering their cytotoxic functions, whereas those 
derived from self-proteins are, usually, not [55,56,57,58]. 
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Figure 16. MHC-I biosynthesis and antigenic peptide binding in the 
endoplasmic reticulum (ER). Trimming of the N-linked glycan by 
glucosidases I and II (GlsI/GlsII) to a single terminal glucose residue (G) 
permits the interaction of the MHC-I heavy chain with lectin-like 
chaperones at several stages during folding and assembly. The initial folding 
events involve the chaperone calnexin (CNX) and allow subsequent 
assembly with β2microglobulin (β2m). The empty heterodimer, which is 
inherently unstable, is then recruited by calreticulin (CRT) via the 
monoglucosylated N-linked glycan to the peptide loading complex (PLC). The 
association of MHC-I/β2m heterodimers with the PLC both stabilizes the 
empty MHC-I molecule and maintains the binding groove in a conformation 
that favors high-affinity peptide loading. These functions are mediated by 
direct interactions between the MHC-I heavy chain and tapasin and are 
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supported by coordinating interactions with CRT and ERp57 in the PLC. 
MHC-I molecules with suboptimal peptides are substrates for UGT1, which 
reglucosylates the heavy chain glycan, allowing reentry of the MHC-I into 
the PLC and exchange for high-affinity peptides. Peptides translocated into 
the ER by the transporter associated with antigen processing (TAP) 
originate primarily from the proteasomal degradation of endogenous 
proteins or DRiPs. These proteins may arise from the translation of either 
self or foreign (i.e., viral) RNA or, in the case of cross-presentation, by 
translocation into the cytosol from endosomes or phagosomes. Many of the 
peptides that are delivered into the ER are longer than the 8–10 residues 
preferred by MHC-I molecules and undergo trimming by ER 
aminopeptidases known as ERAAP/ERAP1 and ERAP2. Finally, high-
affinity peptides bind preferentially to MHC-I molecules in the PLC by a 
tapasin-mediated editing process; MHC-I-peptide complexes are released 
and then transit to the cell surface for T cell recognition by CD8+ T cells 
[58]. 
 
 
1.6 HLA-E: a non-classical HLA class I 
molecule 
In addition to the classical class I genes (HLA-1a), the 
HLA class I region includes a range of “non-classical” 
HLA class I (Ib) molecules such as HLA-E, F and G. The 
exact function of most of these molecules remains poor 
defined; however, several recent studies suggest that 
they have different important immunoregulatory roles by 
acting as ligands for receptors of both the innate and the 
adaptive immune systems [59]. 
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Among these, HLA-E has a wide tissue distribution and 
shares many structural features with the classical class I 
molecules: its heavy chain, non-covalently associated 
with the β2m, is organized into three globular domains 
(alpha-1, 2 and 3) (Fig.17). On the opposite, HLA-E is 
characterized by a limited polymorphism and a relatively 
low cell surface expression compared to its HLA-Ia 
counterpart.  
 
 
Figure 17. HLA-E structure. The heavy chain of HLA-E and β2m are 
shown as violet and cyan ribbons, respectively, with the VMAPRTLFL 
peptide in orange sticks [Adapted from 60]. 
 
Two nonsynonymous HLA-E variants have been 
described, E*0101 and E*0103, that differ for an arginine 
(HLA-ER) or a glycine (HLA-EG) at position 107 of the 
protein, located in the α2 domain of the heavy chain. It is 
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also been suggested that the HLA-EG allele has a higher 
binding affinity for nonamer peptides and are more 
stable than HLA-ER allele resulting in a higher level of 
cell surface expression [61,62].  
The limited polymorphism of the HLA-E peptide binding 
site, located between the α1 and α2 domains, may 
account for the restricted peptide repertoire presented by 
HLA-E molecules. In fact, HLA-E molecules 
predominantly bind a related set of nonamer peptides 
derived from the leader sequence of other HLA class I 
molecules. The signal sequence, processed by signal 
peptide peptidase (SPP), is released into the cytosol 
where it is further trimmed by proteasomes. As for the 
classical HLA-I molecules, their loading onto HLA-E is 
TAP and tapasin-dependent [63,64]. 
Structural analysis of existing peptide-HLA-E complexes 
reveals the presence of two primary anchor residue 
(P2/Met and P9/Leu) as well as additional subdominant 
anchors at position 3, 6 and 7 of the peptide binding motif 
accommodated into well-defined pockets in the HLA-E 
binding groove (Fig.18). Therefore, any variation of these 
molecular adaptations results in a reduction in the 
efficiency of peptide binding to HLA-E as well as in the 
affinity of the HLA-E/receptor interaction [65,66,67]. 
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.  
Figure 18. (A) View of the Class Ia Leader Peptide Bound in the 
HLA-E Groove. The heavy chain is shown in green and the pockets are 
labeled (A)–(E). The peptide is oriented with the N terminus at the left of the 
picture in the A pocket, and the Cα atoms from each residue are numbered 
P1–P9. (B) HLA-E peptide-binding motif. Numbers depict the amino acid 
positions of HLA-E-binding peptides. Upward and downward pointing 
arrows show the position of contact and anchor residues, respectively. Major 
and minor positions are reflected by the length of the arrow. Experimentally 
determined amino acids that are preferred at each anchor residue (top box) 
are shown in comparison with residues in endogenous HLA class Ia leader 
sequence peptides that bind HLA-E (bottom box) [Adapted from 65 and 66].  
 
 
To date, the HLA-E-mediated immunoregulatory 
functions have been primary ascribed to its interaction 
with the CD94/NKG2x heterodimeric receptors expressed 
on NK and a small subset of T cells [68,69,70]. These 
heterodimers consist of one CD94 molecule covalently 
associated to inhibitory (NKG2A-B) or activating 
(NKG2C-E-H) NKG2 molecules. NKG2A molecules 
contain ITIMs in their cytoplasmic tails that lead to 
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inhibition of cytotoxicity, whereas NKG2C interacts with 
the adaptor protein DAP12, which contains ITAM, 
leading to activation of the immune effector cells [71,72]. 
However, the affinity of interaction between HLA-
E/peptide complex and the heterodimer CD94/NKG2 
appears higher for the inhibitory CD94/NKG2A receptor 
[67]. Moreover, the inhibitory signal through NKG2A 
prevails in NK or T cells double positive for both NKG2A 
and NKG2C [73,74].  
Thus, because the expression and function of HLA-E is 
closely related to that of the other HLA class I molecules, 
which provide the nonamer peptides, it acts as a sensor 
by which innate immune NK cells monitor the integrity 
of the HLA class I biosynthesis and their antigen and 
processing pathway on healthy cells. Events such as a 
viral infection or cell transformation, are likely to alter 
the components of the HLA class I antigen processing 
machinery, and to lower the expression of the HLA-E 
molecules thus contributing to unbalance the inhibitory 
signals that keep the NK cells in check [75] (Fig.19). 
However, recent evidence exists that the previously 
mentioned model is not a rule. In fact, some tumor cells 
express HLA-E molecules on their cell surface despite the 
reduction in the classical HLA class I expression [76]. 
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Moreover, virus-infected cells use a similar mechanism to 
escape from immune surveillance. HIV for example 
provides a peptide that stabilizes the cell surface 
expression of HLA-E thus allowing its inhibitory 
function, also in the absence of HLA class I permissive 
alleles [77]. A further case is that of the Cytomegalovirus 
gpUL40 protein from which a HLA-E binding peptide is 
produced in a TAP-independent manner that enhances 
the cell surface expression and the NK-inhibitory 
function of the HLA-E molecules [78]. Michaëlsson et al., 
have also described a nonamer peptide derived from the 
leader sequence of the Heat shock protein (HSP)-60 that 
competes with the class I leader sequence peptides for 
binding to HLA-E molecules. The HLA-E/HSP60-derived 
peptide complex, however, is not efficiently recognized by 
the inhibitory CD94/NKG2A receptor making these 
stressed cells more susceptible to NK [79]. 
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Figure 19. Outcomes of surveillance by NK cells. NK cells survey cells 
for changes in self, represented here by MHC class I and MHC class I–
related molecules (e.g., ULBP, MICA). (1) Depicts an NK cell that is 
inhibited by the HLA-E-specific receptor CD94/NKG2A, and (2) depicts one 
that is inhibited by an HLA-C–specific KIR. The KIR family also includes 
inhibitory receptors with three Ig domains that bind to HLA-A and HLA-B. 
A representative activation receptor (AR) of the natural cytotoxicity receptor 
family is shown in association with an immunoreceptor tyrosine-based 
activation motif (ITAM)-containing subunit, such as DAP12. NK cells 
express multiple activation receptors on their cell surface. NKG2D is a 
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lectin-like receptor that is associated with the subunit DAP10. (A) “Missing 
self”: a global down-regulation of the expression of MHC class I molecules, as 
seen in certain tumors or during viral infections, results in the loss of 
surface HLA-E. The lack of engagement of the inhibitory CD94/NKG2A 
leads to activation of NK cells (A1). The loss of a single class I allotype, such 
as HLA-C, may activate NK cells that express an HLA-C-specific inhibitory 
KIR (A2). (B) “Induced self”: expression of ligands of NKG2D is induced on 
target cells due to cellular stress, transformation, or viral infections and 
results in an activation of NK cells despite the presence of inhibitory 
receptors (Superactivation). It is not known if NKG2D engagement bypasses 
inhibition or if it overrides inhibition by enhancing activation signals from 
other receptors. ULBP is a family of molecules with α1-α2 domains. NKG2D 
binds also to MICA and MICB, which have α1-α2-α3 domains. ULBP and 
MICA/B proteins are not associated with β2-microglobulin and do not bind 
peptides. (C) “Modified self”: stress-induced molecule hsp60 provides a signal 
sequence-derived peptide that binds to HLA-E and prevents recognition by 
inhibitory CD94/NKG2A. This results in activation of NK cells expressing 
CD94/NKG2A (C1) but not of NK cells expressing inhibitory KIR (C2) [75]. 
 
 
Despite HLA-E is well known for its ability of regulating 
innate immune responses, recent evidence has 
established a role for HLA-E also in adaptive immunity. 
HLA-E restricted αβ CD8 T cells have been described 
specific for Mycobacterium tubercolosis, Salmonella 
enterica, Hepatitis C virus (HCV) and Cytomegalovirus 
(CMV) antigens allowing to speculate that HLA-E may 
play a role in T cell defense against viruses or 
intracellular bacteria [80,81,82,83]. Moreover, it has been 
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reported that pathogen or self-derived peptides might be 
presented by HLA-E to CD8 T cells with regulatory 
properties [84,85]. Further studies are, however, needed 
to investigate the immunoregulatory activities of HLA-E 
restricted regulatory CD8 T cells in infection and 
autoimmune disorders. Therefore, all these results 
suggest that HLA-E is a versatile molecule and its 
peptide-binding repertoire is much broader than initially 
described.  
In addition, the existence of a soluble form of the HLA-E 
protein has also been recently identified. The release of 
sHLA-E molecules by melanoma cells, melanocytes and 
IFN-γ-activated or virus-infected endothelial cells might 
presumably counter or promote immune surveillance by 
NK or T cells, thus increasing the unresolved ambiguities 
of HLA-E molecules [86,87,88]. 
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CHAPTER 2 – RESEARCH AIM 
The pivotal role of macrophages in sensing and initiating 
an immune or inflammatory response against any insult 
that can alter the homeostatic balance is widely accepted. 
Despite macrophages rapidly exert their innate immune 
functions by phagocytosis, they also cooperate with both 
innate and adaptive immune cells leading to resolution of 
inflammation and restoring the tissue homeostasis. The 
fine interplay between hematopoietic cells and different 
types of tissue is mediated by ligand/receptor-mediated 
cell-cell interactions as well as through soluble factors. 
Within the immune system, the Natural Killer (NK) cells 
are emerging as the central effectors that provide 
protection against infection and cancer. The cytotoxic or 
regulatory functions of NK cells are tightly dependent on 
separate or cooperative signals derived from different 
receptors. Thus, the interplay existing between NK and 
immune/non-immune cells is strongly dependent on the 
expression pattern of receptors and, their ligands. The 
central role of macrophages and NK cells in the 
regulation of the human immune responses, therefore, 
prompt to focus on the molecular aspects of their 
crosstalk.  
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My PhD thesis project has specifically focused on the 
modulation of the components of the machinary leading 
to processing and presentation of the HLA class I 
antigen, with particular attention on the non-classical 
HLA-E molecule, during the monocytes to macrophages 
differentiation process. HLA-E binds to inhibitory 
NKG2A receptor expressed on the cell surface of a large 
subset of NK cells, and its expression pattern on healthy 
as well as damaged cells is still not fully delineated. 
Moreover, because almost all NK cells express the 
activating NKG2D receptor, the modulation of its ligands 
has been also investigated. The analysis was carried out 
on macrophages generated in vitro from primary human 
blood monocytes or human leukemic cell lines. The 
latters allowed us to analyze the functional outcome of 
the ligand quantitative variation in regulating NK cell 
activity as well as to compare leukemic cells with their 
normal counterpart in the way they modulate the 
expression of the NK ligands.  
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CHAPTER 3 – MATERIALS AND 
METHODS 
3.1 CELL CULTURES AND STIMULATION 
CONDITIONS 
Human peripheral blood mononuclear cells were 
separated on Lympholyte (Cedarlane Laboratories) by 
density centrifugation of heparinized blood from healthy 
donors. Monocytes subpopulations were purified from 
PBMC by positive selection with anti-CD14 mAb coupled 
to magnetic beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). The purity of CD14+ was routinely >90% as 
estimated by flow cytometry using the anti-CD14 mAb 
(Miltenyi Biotec). Cells were seeded at concentration of 
106 cells/ml in RPMI 1640 supplemented with 10% FBS, 
2 mM L-glutamine, 25 U/ml penicillin and 25 U/ml 
streptomycin (all purchased from Gibco, Invitrogen, 
Carlsbad, CA, USA) in cell culture plates and treated for 
9 h with LPS (0.05 µg/ml; Sigma-Aldrich), PMA (80 nM; 
Sigma-Aldrich), or differentiated for 7 days with 
recombinant human GM-CSF (100 ng/ml; Miltenyi 
Biotec) or M-CSF (100 ng/ml; Miltenyi Biotec).  
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The U937 and THP1 cell lines were obtained from ATCC, 
cultured in RPMI 1640 supplemented with 10% FBS. 
U937 and THP1 cells (5x105/ml) were left untreated or 
treated for the indicated time with GM-CSF (25 ng/ml), 
1,25-dihydroxyvitamin D3 (10 nM; Sigma-Aldrich), a 
combination of GM-CSF+Vitamin D3, PMA (80 nM for 
U937 and 100 nM for THP1) or IFN- (250 U/ml; BD 
Pharmingen).  
Natural Killer cell populations were obtained by a 10-day 
co-culture of PBMC with irradiated (30 Gy [3000 rad]) 
Epstein-Barr virus–transformed B-cell line RPMI 8866 
(4:1 ratio), in RPMI 1640 medium supplemented with 
10% FBS and 2 mM glutamine, as previously described 
[89]. Cultures were used at day 10, and were routinely 
more than 80% NK (CD56+CD16+CD3−), as assessed by 
immunostaining and flow cytometry analysis. 
Cells were maintained in a humidified atmosphere of 5% 
CO2 at 37°C. 
  
 
49 
 
3.2 RNA isolation and quantification by 
Real Time (RT) – PCR analysis 
Total RNA was isolated from monocytes, U937 and THP1 
cell lines using the Trizol reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions. 
RNA quality was monitored by running the aliquots of 
each sample in 1% agarose gel and by spectrophotometric 
analysis. HLA-E transcripts were evaluated using real-
time PCR (HS00428366, Applied Biosystems). One 
microgram of total RNA from each sample was used to 
perform reverse transcription using the High-Capacity 
cDNA Reverse Trascription kit (Applied Biosystems) 
according to the manufacturer’s instructions. Real-time 
PCR was performed in ABI PRISM 7300 Sequence 
Detection Systems (Applied Biosystems) using 
TaqMan®2X Universal Master Mix and the following 
TaqMan® Gene Expression Assays: HLA-E, Hs00428366; 
HLA-B, Hs00741005; HLA-A, Hs01058806 (Applied 
Biosystems). Each sample was assayed in triplicates. The 
thermal cycling conditions were set up sequentially as 
follows: denaturating at 95°C for 10 minutes and 60 
cycles of 95°C for 15 seconds and 60°C for 1 minute. The 
fold change of the HLA genes in the samples was 
calculated using the 2-ΔΔCT method. All values were 
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normalized to endogenous control GAPDH (Hs99999905, 
Applied Biosystems) and were expressed in arbitrary 
units. 
 
 
3.3 Western blot analysis 
Total protein extracts were obtained by lysing cells for 30 
min at 4°C in lysis buffer (20 Mm Tris-HCl pH 8, 137 mM 
NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA) in 
the presence of protease and phosphatase inhibitors 
(Sigma-Aldrich). Culture supernatants were collected at 
the indicated times after activation and concentrated 
(10X) using Amicon Ultra Centrifugal Filters (Millipore, 
Bedford, MA). Proteins were resolved by SDS-PAGE and 
immunoblotting was performed on nitrocellulose 
membranes (GE Healthcare, Piscataway, Nj, USA) using 
the following primary antibodies: anti–HLA-E (MEM-
E/02, kindly provided by Prof. Vaclav Horejsi, Prague, 
Czech Republic), anti–HLA-B/C (HC-10) and anti-HLA-A 
(HCA2) (purified from HC10 and HCA2 hybridoma 
supernatants), anti-Hsp60 (StressMarq Bioscience Inc, 
BC, Canada), anti-β2m and anti-p21 (Santa Cruz 
Biotecnology, Santa Cruz, CA), anti-ERp57 (kindly 
provided by Dr. Doriana Fruci, Rome, Italy). Anti-mouse 
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or anti-rabbit IgG, HRP-linked Abs (GE Healthcare) were 
used as secondary Abs in chemiluminescent Western blot 
assays using the Pierce ECL system (Thermo Scientific). 
Protein levels were normalized for GAPDH (Santa Cruz 
Biotechnology, Santa Cruz, CA) protein levels using 
Image J version 1.45 software (developed at the National 
Institutes of Health). 
 
 
3.4 Flow cytometry 
Cells were harvested, washed twice with PBS containing 
1% BSA and 0,1% NaN3 and then incubated on ice for 30 
minutes with a saturating concentration of the primary 
antibody. After 3 washes, cells were incubated with an 
FITC-labeled goat anti–mouse IgG antibody (Jackson 
ImmunoResearch Laboratories) at 4°C for 30 minutes. 
Finally, cells were suspended in 1% paraformaldehyde in 
PBS. Negative controls were performed by incubation of 
the cells with isotype-matched control antibodies. The 
mouse mAbs used for this study were anti-CD11b and 
anti–CD14 (Miltenyi Biotec), anti-HLA-E (3D12; 
BioLegend),  anti-MICA and anti-MICB, anti-ULBP1, 2, 
3 (all from R&D Systems). Fluorescence was measured 
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on 10 000 cells/sample using a FACScalibur and analyzed 
using CellQuest software (BD Biosciences).  
 
 
3.5 Cytotoxicity assays 
HeLa or U937 target cells (untreated or differentiated as 
described above) were labelled with 51Cr (PerkinElmer, 
MA, USA) (100 uCi/1x106 cells) for 1h and 15’ at 37°C. 
When indicated, cells were pre-incubated overnight with 
60 µg/ml of the HLA-B7 [VMAPRTVLL] or Hsp60 
[QMRPVSRVL] signal peptides before labeling. HeLa 
cells were pre-incubated 20’ at 37°C with supernatants 
from either differentiated or untreated U937 cultures. 
Serial dilutions of in vitro expanded NK effector cells 
were plated in U-bottom 96-well plates in RPMI 1640 
medium supplemented with 10% FBS, 2 mM glutamine 
and 10 mM Hepes and incubated with saturating 
concentration of anti-NKG2A (Z199 clone, kindly 
provided by Prof. Miguel Lopez-Botet), anti-CD56 mAb 
(C218 clone, kindly provided by Prof. Bice Perussia), or 
medium, for 30’ at 4°C, before adding target cells. After a 
4 hr incubation at 37°C, 30 µl of supernatants were 
transferred to 96-well Lumaplate (PerkinElmer) and 
released radioactivity was counted with a -counter 
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instrument (TopCount, PerkinElmer, Waltham, MA). 
Percent specific lysis was calculated according to the 
formula: % specific lysis = (experimental release cpm - 
spontaneous release cpm)/(maximum release cpm -
spontaneous release cpm) x 100. Spontaneous release 
never exceeded 5% of total release. 
 
 
3.6 Statistical analysis 
Results are shown as the mean and standard error of the 
mean from at least three independent repeated 
experiments. The level of significance (P values) between 
treated and untreated groups was analyzed using the 
Student’s t-test, and P < 0.05 was considered significant. 
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CHAPTER 4 – RESULTS 
4.1 Peripheral blood CD14+ monocytes up-
regulate HLA-E molecules following LPS or 
PMA activation 
Perypheral blood monocytes from nine individuals were 
treated with LPS (0.05 µg/ml), PMA (80 nM) or medium 
alone (MED) for 9h and the expression of HLA-E was 
evaluated using the MEM-E/02 antibody.  The expression 
of HLA-E molecules is induced by LPS and, even more, 
by PMA (Fig.20 A-B). On the opposite mRNA measured 
by qRT-PCR was highly induced by LPS but significantly 
down-regulated by PMA treatment for 9h (Fig.20 C). To 
verify whether the kinetics of PMA induction was 
anticipated compared to LPS, mRNA level was evaluated 
at 1 and 3 hours after treatment. The level of HLA-E 
mRNA was indeed increased following 1h treatment and 
already decreased after 3h whereas the adherence on the 
plastic plate acted as partial stimulus since the HLA-E 
mRNA expression in the control (medium alone) 
increased during time (Fig.20 D). Therefore, the stimulus 
induced by PMA under the conditions used here seemed 
to be more effective than LPS in inducing the up-
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regulation of the HLA-E molecules. This prompted us to 
differentiate monocytes in vitro to verify whether the 
expression of HLA-E could be a marker of differentiation. 
 
 
Figure 20. (A) Western blot analysis showing HLA-E in cell lysates from 
monocytes plated and treated for the indicated time with culture medium 
alone (MED), 80 nM PMA or 0.05 µg/ml LPS. Cell lysates were 
immunoblotted using MEM-E/02 (as anti-HLA-E mAb). GAPDH immunoblot 
was used as loading control. (B) Densitometric analysis of western blot. 
Immunoreactive bands were normalized to GAPDH. Histograms represent 
HLA-E protein levels as mean ± SD in monocytes from nine healthy donors. 
(C) qRT-PCR analysis of HLA-E mRNA in the same sample as above. 
Untreated control (MED) level was set to 1. (D) qRT-PCR showing the HLA-
E mRNA level in monocytes from four healthy individuals activated by PMA 
or cultured with medium alone for 1 and 3 hours. Data were normalized to 
GAPDH and expressed as relative to control (MED 1h) arbitrarily set at 1. 
Statistical significance: *p<0.05 and **p<0.01 compared to untreated control 
(MED). 
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4.2 HLA-E and HLA class I antigen 
processing machinery components are 
strongly modulated during the monocyte to 
macrophage differentiation process 
To analyze in more details the dynamics of the HLA-E 
up-regulation and its subsequent functions in the 
monocyte-differentiated cells, the human monocytic cell 
lines U937 and THP1 have been differentiated to 
monocytes or macrophages. In the former case, the 
hormonally active form of Vitamin D3 (1,25-
dihydroxyvitamin D3) was used in combination with GM-
CSF for 96h. The differentiation was monitored through 
the up-regulation of the monocyte-associated cell surface 
antigens, CD14 and CD11b, which was high in both cell 
lines after 96h treatment (Fig.21 A). Interestingly, while 
the U937 cell line, consistently with the results reported 
by others [90,91,92], requires both agents to reach the 
maximal expression of CD14 and CD11b on the cell 
surface (Fig.21 A), THP1 does not require the presence of 
GM-CSF. However, we decided to use the same protocol 
for both and all the analyses in U937 and THP1 cells 
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were carried out using 10 nM VitD3 and 25 ng/ml GM-
CSF for 96h if not otherwise specified. By contrast, the 
differentiation into a macrophage-like phenotype was 
induced by PMA (80 nM) treatment for 96h, the time at 
which the expression of the CD11b macrophage marker 
was maximum and all cells still alive (Fig.21 A). As 
expected for macrophages, the expression of CD14 was 
low. 
 
Next, we compared the expression of HLA-E proteins and 
a number of molecules either involved in HLA class I 
antigen processing and presentation or stress-induced. 
U937 and THP1 cells were left untreated or exposed for 
96h to a combination of GM-CSF plus VitD3 or PMA 
alone and a western blotting analysis was performed on 
total-cell lysates (Fig.21 B and C). There was no 
substantial effect of GM-CSF+VitD3 on HLA-E 
expression as well as on the other molecules. By contrast, 
the level of HLA-E as well as ERp57,  involved in antigen 
presentation, increased after PMA treatment for 96h. 
Moreover, there was not a significant up-regulation of the 
HLA-B/C class I and Hsp60 molecules that are known to 
act as peptide donors for the HLA-E proteins, in PMA-
treated cells. PMA also caused a major increase in p21 
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expression, that is consider to play a critical role in cell 
cycle arrest and differentiation of PMA-treated monocytic 
cell lines, suggesting that the HLA-E up-regulation is a 
consequence of the differentiation program. This 
prompted us to differentiate human blood monocytes in 
vitro to verify whether the results were reproducible in a 
more physiological setting. Monocytes from four different 
donors were treated for 7 days with GM-CSF and the 
expression of HLA-E and the other molecules, as above, 
was evaluated in comparison with the corresponding ex 
vivo isolated monocytes. Immunoblotting confirmed a 
strong increase of the HLA-E protein in GM-CSF 
monocyte-derived macrophages (MDM) and similar, but 
less marked changes, were noted in the other molecules 
belonging to the HLA class I antigen processing and 
presentation machinery or stress-induced (Fig.21 B and 
C).   
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Figure 21. (A) Analysis of differentiation markers. U937 and THP1 cell 
lines were cultured for 96h with medium alone (MED), 25 ng/ml GM-CSF, 10 
nM 1,25-dihydroxyvitamin D3 (VitD3), a combination of GM-CSF and VitD3, 
or 80 nM PMA. Surface expression of CD14 and CD11b was quantified by 
flow cytometry using APC- conjugated CD14 or CD11b mAbs or an isotype-
matched control antibody (histograms in gray). (B) Expression of HLA-E 
and HLA class I antigen processing machinery components during the 
monocyte differentiation. Western blot analysis showing Hsp60, ERp57, 
HLA-B/C, HLA-E and p21 in cell lysates from U937 and THP1 cells treated 
for 96h with medium alone, a combination of GM-CSF and VitD3, or PMA.  
The same proteins were analyzed in cell lysates from freshly isolated 
peripheral blood monocytes or monocyte-derived macrophages differentiated 
by 50 ng/ml GM-CSF for 7 days. Immunoblots were reprobed with anti-
GAPDH mAb to compare protein loading among different samples. (C) 
Densitometric analysis of the blots. Immunoreactive band were normalized 
to GAPDH. The bars represent mean values (±SD) of the analysis from four 
independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate 
statistically significant differences as compared to untreated control.  
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In order to elucidate the mechanisms producing the 
increase in the total HLA-E protein levels in U937 
undergoing PMA-induced differentiation, which seems 
not paralleled by the classical HLA class I molecules, a 
time course of effect of PMA on HLA-E and HLA-A, B, C 
expression was performed. A significant increase in the 
HLA-E protein level was already observed 24h after PMA 
treatment. In parallel, as positive reference, the up-
regulation of HLA-E was induced by activation of the 
cells with 250 U/ml IFN-γ for 48h (Fig.22 A and B). 
Treatment with PMA also produced the up-regulation of 
β2-microglobulin but with a slower kinetics (Fig.22 A and 
B). Interestingly, the amount of other HLA class I 
molecules (HLA-A, B, C) as detected by HC10 (specific for 
heavy chains of HLA-B, C alleles) and HCA2 (specific for 
HLA-A) antibodies was no significantly modified. As 
expected, IFN-γ activation considerably increased the 
levels of classical HLA class I protein (Fig.22 A and B).  
A quantitative RT-PCR showed how mRNA 
concentration mirrored the results obtained at protein 
levels with a significant increase of the HLA-E specific 
transcript but not of that specific for classical HLA class I 
(Fig.22 C). Conversely, the IFN-γ induces a strong up-
regulation of both HLA-E and HLA-A, -B molecules 
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(Fig.22 C). This observation suggests that gene 
transcription can be in part responsible for the increase 
of the HLA-E molecules in PMA-treated U937 cells. 
 
 
Figure 22. (A) Western blot analysis showing HLA-A, HLA-B/C, HLA-E 
and β2-microglobulin in cell lysates from U937 treated for the indicated time 
with 80 nM PMA or for 48 hours with 250 U/ml IFN-γ. Immunoblots were re-
probed with anti-GAPDH mAb to compare protein loading among samples. A 
representative immunoblot of 4 indipendent experiments is shown. (B) 
Densitometric analysis of the blots. Immunoreactive band were normalized 
to GAPDH. The bars represent mean values (±SD) of the analysis from four 
independent experiments.  (C) HLA-E, HLA-A and HLA-B gene 
transcription in PMA differentiated U937 cells. Cells were differentiated for 
the indicated times with 80 nM PMA; stimulation with IFN-γ has been 
taken as positive reference. Total RNA was purified from the respective cell 
pellets and analyzed by qRT-PCR for the expression of HLA-E, HLA-A and 
HLA-B. Results were normalized to GAPDH expression levels. Untreated 
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cells were arbitrarily set at 1. Values are mean ± SD of four experiments. *p 
< 0.05, **p < 0.01 and ***p < 0,001  represent a significant difference as 
compared to untreated control.  
 
 
4.3 The NKG2A and NKG2D ligand 
expression is differently modulated on the 
cell surface of human monocytic cell lines 
or primary monocytes undergoing 
differentiation. 
It was interesting to know whether PMA or GM-CSF-
induced up-modulation of the HLA-E was paralleled by 
an increased expression of such molecules on the cell 
surface. HLA-E expression was investigated by flow 
cytometry with the mAb 3D12, which is considered to be 
specific for HLA-E, on the cell surface of either human 
monocytic cell lines or primary human 
monocyte/macrophage cells. The expression of the ligands 
of one of the major NK activating receptor (NKG2D) was 
also investigated. 
Figure 23 shows that U937 and THP1 cells share a basal 
expression of HLA-E on the cell surface. Unexpectedly, 
neither the combination of GM-CSF plus VitD3 nor PMA 
alone further increased HLA-E cell surface expression, 
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which is not consistent with the immunocytochemistry 
analysis on the total protein extract, performed before. 
Moreover, both the monocytic leukemia cell lines 
expressed the UL16-binding proteins (ULBP-1, 2, 3), but 
not the MHC class I-related molecules (MICs) that are 
known to bind the NK-activating receptor NKG2D. 
Interestingly, the ULBPs were strongly down-regulated 
when the cells were differentiated by PMA. 
All the analyses were then repeated on freshly human 
blood monocytes as well as on GM-CSF monocyte-derived 
macrophages, where the expression pattern of NKG2A 
and NKG2D ligands did not reproduce that obtained on 
the cell lines. In fact, primary monocytes expressed only 
a small amount of HLA-E on the cell surface and, 
consistently with immunocytochemistry, FACS analysis 
confirmed that GM-CSF-induced differentiation produced 
a significant increase in membrane-bound HLA-E 
compared with constitutive levels (Fig.23). In addition, 
human blood monocytes did not express the ligands for 
the NKG2D receptor although the ULBP-1, 2, 3 
molecules were strongly up-regulated by GM-CSF 
(Fig.23). 
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Figure 23. Cell surface expression of NKG2A and NKG2D ligands. U937 
and THP-1 cells were cultured for 96h with medium alone, a combination of 
GM-CSF and VitD3, or PMA. Human peripheral blood monocytes were 
differentiated by GM-CSF for 7 days. Membrane-bound NKG2A and NKG2D 
ligands were analysed by flow cytometry following cell immunostaining with 
specific mAbs or isotype-matched control antibodies. One representative 
experiment out of 3 performed is shown here. 
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4.4 Modulation of the sensitivity to NK-
mediated lysis in “untreated” or 
“differentiated” U937 cells 
To analyze whether NK cells could kill the human 
monocytic cell line U937 depending on its differentiation 
state, CD94/NKG2A expressing polyclonal NK cells were 
used as effectors in cytolytic assays against U937 cells 
untreated or differentiated for 96h by GM-CSF+VitD3 or 
PMA. As shown in Figure 24A, untreated and GM-
CSF+VitD3-treated cells displayed similar susceptibility 
to NK-mediated lysis. By contrast, upon PMA-induced 
differentiation, their susceptibility to NK lysis was 
significantly decreased. These results suggested a direct 
correlation between the susceptibility to NK lysis and the 
expression level of ULBP molecules on the cell surface of 
U937 cells, previously described. Moreover, their 
susceptibility to lysis inversely correlated with the level 
of expression of total HLA-E molecules, although the 
FACS analysis did not show any modulation in the HLA-
E cell surface expression after PMA treatment. 
Therefore, to evaluate the contribution of HLA-E 
molecules in inhibiting the NK cytotoxic activity, 
cytolytic assays were performed in the presence of mAbs 
specific for the inhibitory NK cell receptor CD94/NKG2A 
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or anti-CD56 mAb as control. As shown in Figure 24B, it 
is evident how the PMA-differentiated U937 cells were 
much less prone to lysis by NK cells although the anti-
NKG2A antibody was effective in restoring the lysis in 
these cells as well as in their untreated counterparts. 
 
 
 
Figure 24. (A) NK cytotoxic activity against U937 cells untreated or 
stimulated for 96h with GM-CSF+VitD3 or PMA. (B) Cytotoxic activity 
against undifferentiated and PMA-differentiated U937 cell line, in the 
presence of anti-NKG2A or anti-CD56 mAb.  
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To address this point further, PMA-treated and control 
U937 cells were pulsed O.N. with HLA-E specific 
peptides before to be tested. Two peptides were used: the 
natural HLA-E ligand, HLA-B7 signal peptide, or that 
derived from Hsp60 that is also a good binder for HLA-E 
but not for the CD94/NKG2A receptor. Interestingly, the 
presence of HLA-B7 peptide (Fig.25 A), compared to 
control Hsp60 signal peptide (Fig.25 B), induced a higher 
protection from NK lysis of both untreated and PMA-
treated cells. Again, blocking NKG2A on effector cells 
significantly restored cell lysis although there is again no 
difference between the differentiated and not 
differentiated target cells (Fig.25 A-B). These results 
confirmed previous findings that undifferentiated and 
PMA-differentiated U937 cells express a same amount of 
cell surface functional HLA-E molecules that are, 
however, prone to binding HLA-E-restricted peptides to 
ensure their optimal function. 
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Figure 25. Cytotoxic activity against undifferentiated and PMA-
differentiated U937 cell line, in the presence of anti-NKG2A or anti-CD56 
mAbs. U937 cells were pulsed with HLA-B7 (A) or Hsp60 (B) peptides 
before to be used as target. 
 
 
4.5 Macrophages release a soluble form of 
HLA-E molecules which does not appear to 
influence target cell susceptibility to NK 
cells 
The above data indicated that the PMA induced a strong 
increase of the HLA-E transcript and intracellular 
protein levels that were not translated into a higher 
expression of cell surface HLA-E molecules on both U937 
and THP1 human monocytic cell lines. Therefore, we 
asked whether part of the over-expressed HLA-E 
molecules might be released a soluble molecules in the 
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culture medium. To this aim, a Western blot analysis was 
performed, using the specific anti-HLA-E mAb MEM-
E/02, on the supernatants of U937 and THP1 cells 
cultured for 96h with medium alone, a combination of 
GM-CSF+VitD3 or PMA. Cell lysate from U937 cells was 
also loaded onto a 12% polyacrylamide gel as a further 
control. As shown in Figure 26A, a band of lower 
molecular mass than the full-length protein was detected 
in the culture supernatants of PMA-differentiated cells, 
compatible with a proteinase-dependent shedding form. 
Interestingly, a similar band could be detected in culture 
supernatants of primary human blood monocytes 
differentiated for 7 days by GM-CSF or M-CSF (Fig.26 B) 
suggesting that the release of soluble HLA-E molecules 
could be an event normally associated to monocyte-
macrophage differentiation. 
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Figure 26. Production of sHLA-E by macrophages. (A) Cell culture 
supernatants were collected from U937 and THP1 cells that were cultured 
for 96h with a combination of GM-CSF+VitD3, PMA alone, or left untreated 
(UNT). sHLA-E was then detected by Western blotting in concentrated (10x) 
supernatants (10 µL/sample) with the mAb MEM-E/02. A cell lysate from 
U937 cells was loaded as a control. (B) Culture supernatants of the GM-CSF 
or M-CSF monocyte-derived macrophages were collected and analyzed, as 
previously described. A total cell lysate from GM-CSF-treated monocytes 
was loaded as a control. One representative experiment out of three 
performed is shown here. 
 
 
Next, a cytotoxicity assay was performed to evaluate a 
possible protective effect of sHLA-E molecules against 
CD94/NKG2A-dependent NK cell lysis. The cytotoxic 
activity of NK cells toward HeLa cells, which do not 
express HLA-E molecules on the cell surface, was 
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measured in conventional medium or in the presence of 
cell-conditioned medium containing sHLA-E derived from 
PMA-differentiated U937 cell culture supernatant. As 
shown in Figure 27A, HeLa cells were efficiently killed by 
NK cells with no effect of the anti-NKG2A-blocking mAb, 
which is consistent with the absence of functional HLA-E 
molecules at the cell surface. This experiment also 
indicated that cell lysis decreased when sHLA-E was 
present in the culture medium, although this protection 
was not apparently provided by sHLA-E molecules 
themselves since blocking NKG2A with a specific mAb 
did not restore NK-mediated HeLa lysis (Fig.27 B). This 
result suggested that the culture supernatant of PMA-
differentiated U937 cells contained one or more factors, 
different from sHLA-E, able to affect the NK-cell cytolytic 
potential. 
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Figure 27. Effect of sHLA-E on NK cytotoxicity against HeLa cells that do 
not express cell surface HLA-E molecules. HeLa cells were labeled with 51Cr 
and preincubated with (A) normal culture medium or (B) conditioned 
medium, containing sHLA-E, from PMA-differentiated U937 cells for 20 
minutes a RT before incubation with NK cells for 4 hours at 37ºC. Blocking 
experiments were performed after preincubation of NK cells with medium 
alone, anti-NKG2A or anti-CD56 mAbs. 
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CHAPTER 5 – DISCUSSION 
HLA-E molecules are becoming more and more 
interesting in the immune network because of their 
function as ligand for canonical NK inhibitory receptor 
CD94/NKG2A but also, as more recently demonstrated, 
because they can engage the TCR on CTL [80-83] or 
favoring the expansion of regulatory T cells [84,85]. 
Despite its little polymorphism, the HLA-E gene has 
been found to be associated with several diseases [93-
103] suggesting an active role in the pathogenic 
mechanisms. Nevertheless, little is still known about the 
regulation, the function and the peptidome of the HLA-E 
molecules. Here we add a little tile on the puzzle showing 
how these molecules are up-regulated along the 
monocyte/macrophage differentiation process. 
Interestingly, their expression profile as well as the 
NKG2D ligand expression pattern on primary cells do not 
overlap with the myeloid leukemia cell lines undergoing 
differentiation used here suggesting that their regulation 
is of pivotal importance for tumor immune surveillance. 
The present findings show that human blood monocytes 
significantly up-regulate HLA-E molecules as well as 
other HLA class I antigen processing and presenting 
machinery components during their in vitro 
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differentiation to macrophages by GM-CSF, which is 
known to induce an M1-like polarized phenotype. Most 
importantly, the increase of intracellular HLA-E levels is 
translates into a higher cell surface expression, 
highlighting the potential role of HLA-E in macrophage 
immunobiology as also suggested by others for M1-
polarized macrophages [104]. Furthermore, we found 
that GM-CSF induced up-regulation of ULBP-1, 2, 3 
molecules, the ligands for NKG2D, an NK activating 
receptor. These results lead us to speculate about the 
existence also in humans of a complex crosstalk, recently 
described in mice, by which macrophages activate NK 
cells that can recognize tumor or infected cells 
meanwhile protecting themselves by up-regulation of 
HLA-E molecules [105]. 
However, such a scenario does not occur in both the 
human monocytic cell lines (U937 and THP1) used here 
as a model. Both these myeloid leukemia cell lines 
express HLA-E on the cell surface. Interestingly however, 
when treated with PMA that induce their differentiation 
to a macrophage-like cell type, the high increase of the 
intracellular pool of the HLA-E molecules observed is not 
paralleled by a substantial increase on the cell 
membrane. The retention of these proteins within tumor 
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cells is a frequently reported event and there might be 
many possible explanations for this. The more likely 
hypothesis is that the peptide repertoire changes 
dramatically in tumor cells and a limiting amount of 
optimal HLA-E peptides is available to binding. This 
seems however unlikely in our case since classical HLA 
class I, the major productive source of peptides for HLA-
E molecules, as well as the β2m and ERp57 were strongly 
increased by treatment with PMA. So, as previously 
reported, tumor cells seem to activate some mechanisms 
that do not allow the over-expression of the HLA-E 
molecules on the cell membrane despite the large 
intracellular pool and the efficiency of the HLA class I 
antigen processing and presenting machinery [106]. 
Moreover, it has been demonstrated that HLA-E 
molecules are present on the cell surface in different 
conformations [107], some of which probably devoid of 
classical peptides. These findings suggest that we are 
only at the beginning of our understanding of the 
multifaceted role of these molecules which appear to be 
at the crossroads between protection by NK killing and 
activation of specific functions in T lymphocytes. It was 
therefore interesting to verify whether the newly 
synthesized molecules, maybe undetectable on the cell 
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surface because of their non-canonical conformation, 
were functional, at least in terms of protection from NK. 
Here we show how the PMA-differentiated U937 cells are 
lysed less efficiently than the undifferentiated 
counterpart, and this is probably due to the strong down-
modulation of the ligands (ULBPs) for the activating 
receptor NKG2D. However, blocking the NKG2A receptor 
was restoring lysis in both PMA-treated and 
undifferentiated cells at about the same efficiency, 
suggesting that the interaction HLA-E – CD94/NKG2A 
does occur but it can probably be ascribed to a subset of 
the HLA-E molecules already present in the 
undifferentiated cells. Moreover, the use of canonical 
binders for HLA-E, i.e. HLA-B7 peptides, makes both 
targets more resistant to NK lysis indicating that the cell 
surface HLA-E molecules in these myeloid leukemia cell 
lines were prone to bind exogenously provided peptides. 
It remains to understand what is the fate of the 
increased intracellular pool of the HLA-E molecules 
induced by PMA-treatment.  
One possibility is that, at least part of these molecules, 
transits through the cell membrane. This seems indeed to 
be the case since we show here for the first time that 
these cells produce a soluble form of the HLA-E protein 
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with a molecular mass of about 37-41 kDa. Interestingly, 
the same phenomenon is observed in the culture 
supernatants of GM-CSF monocyte-derived macrophages 
suggesting that the release of sHLA-E is a cellular event 
due to the differentiation to macrophages both for normal 
monocytes as well as for PMA-treated leukaemic cells. 
The shedding of cell surface HLA-E was also reported for 
melanocytes, melanoma or endothelial cells and 
attributed to a matrix metalloproteinase activity [86-88], 
suggesting that these proteases might also be responsible 
for the release of sHLA-E by macrophages. The 
generation of soluble β2m-free classical HLA class I 
molecules by metalloproteinase has also been described 
in leukemia cells [108]. Moreover, it has been suggested 
that the soluble β2m-free HC with bound peptide can re-
associate with exogenous β2m producing a stable and 
probably functional complex [109]. 
Our data suggest that the macrophage-released sHLA-E 
forms do not provide protection to HLA-E negative target 
cells against CD94/NKG2A-dependent NK cell 
cytotoxicity. Therefore, the meaning of these sHLA-E 
molecules remains to be elucidated and will be probably 
dependent on their binding with the β2m and/or on the 
nature of the bound peptides. A further possibility is that 
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the number of HLA-molecules on the cell surface of 
macrophages is strictly regulated and an excess of these 
molecules could be detrimental for the fine-tuning of the 
crosstalk between macrophages and other cells of the 
immune systems such as, for example, regulatory T cells.  
In conclusion, we have shown in this study how HLA-E 
molecules can be up-regulated during the monocyte to 
macrophage differentiation process and that, at least 
part of these molecules, are released in a soluble form. It 
can be hypothesized that HLA-E, besides the protective 
effect by NK killing, may regulate multiple functions of 
macrophages. Both membrane-bound and soluble HLA-E 
can contribute to make macrophages, which are 
professional APC, eventually able to interact with CTL 
or, in addition, T cells with regulatory functions that are 
restricted for HLA-E. 
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